NANJING, CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Triastek's 3D printed gastric retention product T22 received IND clearance from the FDA, becoming the world's first 3D printed gastric retention...
The study verified the ability for Triastek's 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in the colonNanjing, July 21, 2023 (GLOBE NEWSWIRE) --...
The study verified the ability for Triastek's 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in the colon Nanjing, July 20, 2023 (GLOBE NEWSWIRE) --...
Eli Lilly has identified 3D printing as a way to get drugs to specific regions of the gastrointestinal tract, leading it to team up with Triastek to work on the targeted release of molecules in the intestine.
Triastek, Inc. and Siemens Ltd., China have signed a collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's 3D printing and digital pharmaceutical technologies and Siemens' expertise in automation and digitization is expected to lead to innovative and transformative solutions for the development and manufacturing of pharmaceuticals.
NANJING, China, March 17, 2022 /PRNewswire/ -- Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies and Siemens' global leadership in automation and digitization is expected to lead to innovative and transformative solutions for the development and manufacturing of pharmaceuticals.